CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

Clinical trial NCT04626739 · UNKNOWN

Trial details

NCT number: NCT04626739
Sponsor: Hebei Senlang Biotechnology Inc., Ltd.
Status: UNKNOWN
Phase: Early Phase 1
Study type: INTERVENTIONAL

Refractory Indolent Adult Non-Hodgkin Lymphoma

Start date: 2020-04-01
Primary completion: 2023-03-30
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.